Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Photo: Mike Segar/Reuters/Ritzau Scanpix

US-based pharmaceutical company Eli Lilly has presented results from the third quarter of 2021, and in connection with the release, expectations for earnings per share have been adjusted.

Thus, the expected earnings per share (non-GAAP) for 2021 are now USD 7.95-8.05, up from the previous USD 7.8-8.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs